Neumora Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
K2 HealthVentures Equity Trust reports a 3.1% beneficial ownership stake in Neumora Therapeutics via debt conversion rights.
NASDAQ
A significant Schedule 13G filing reveals Invus entities and Raymond Debbane collectively hold a 4.7% stake in Neumora Therapeutics, Inc. as of March 31, 2026.
NASDAQ
Raymond Debbane and affiliated entities, collectively known as the Invus Group, have disclosed a beneficial ownership of 5.4% in Neumora Therapeutics, Inc.
NASDAQ
K2 HealthVentures Equity Trust LLC and its managing members have disclosed a 6.6% beneficial ownership in Neumora Therapeutics, Inc. common stock.
NASDAQ
FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 2.2% of Neumora Therapeutics Inc.'s common stock as of March 31, 2025.
NASDAQ
Paul L. Berns has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Neumora Therapeutics, Inc. as of December 31, 2024.